热门资讯> 正文

Niagen Bioscience表示Niagen IV已在全国近600家诊所使用

2025-05-05 20:52

Niagen Bioscience (NASDAQ:NAGE) announced on Monday the continued expansion of its clinical footprint, with additional new clinics now offering pharmaceutical-grade Niagen IV and injections featuring patented nicotinamide riboside.
These new providers join a growing network of almost 600 clinics nationwide offering the pharmaceutical-grade NAD-boosting Niagen IV therapy.
Niagen Bioscience (NASDAQ:NAGE) shares were up 0.37% in premarket trading.

More on ChromaDex

ChromaDex Capitalizes On Longevity Boom, But Valuation Remains High
ChromaDex Corporation 2024 Q4 - Results - Earnings Call Presentation
ChromaDex Corporation (CDXC) Q4 2024 Earnings Call Transcript
ChromaDex GAAP EPS of $0.09 beats by $0.07, revenue of $29.1M beats by $2.59M
Seeking Alpha’s Quant Rating on ChromaDex

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。